Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02332642

Acronym

ImmunoPAX

Enrollment

Registered

2015-01-07

Start date

2014-11-30

Completion date

2016-12-31

Last updated

2017-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immuno-monitoring

Brief summary

This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.

Interventions

OTHERImmuno-monitoring

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* histologically defined metastatic melanoma patients (AJCC stage IV) * aged 18 to 80 years * at least one prior systemic anti-melanoma therapy; if BRAFV600 positive, at least one prior BRAFi therapy

Exclusion criteria

* therapy-naive patients * any contra-indications for (specific) systemic chemotherapy

Design outcomes

Primary

Measure	Time frame
Immuno-monitoring	Immediate

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026